文献速递肿瘤 PET/CT

PET-CT 用于头颈癌分期与复发检测

PET-CT for Staging and Detection of Recurrence of Head and Neck Cancer.
PubMed 文献 · Semin Nucl Med · 2020-10-22

本文综述了 FDG PET-CT 在鳞状细胞头颈癌分期、复发检测及监测中的作用。FDG PET-CT 对 T4 期下咽癌、鼻咽癌及 N3 淋巴结病变分期有重要作用,能有效准确检测复发;放化疗后 12 周颈部无 FDG 摄取的晚期淋巴结病变患者无需颈清扫。在无症状患者常规随访中复发检出率不足 1%,FDG PET-CT 可能有助于对幸存者进行风险分层。

要点

  • FDG PET-CT 对 T4 下咽癌、鼻咽癌及 N3 淋巴结病变分期有重要作用。
  • 放化疗后 12 周颈部无 FDG 摄取的晚期淋巴结病变患者无需颈清扫。
  • 无症状患者常规随访复发检出率不足 1%,PET-CT 可能助于风险分层。

核心结论

  • FDG PET-CT 是鳞状细胞头颈癌患者的主要检查之一,在分期、复发检测及监测中有重要作用。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • FDG PET-CT 对 T4 期下咽癌、鼻咽癌及 N3 淋巴结病变分期有重要作用。
  • FDG PET-CT 能有效准确检测复发,并在鳞状细胞头颈癌幸存者监测中有新兴作用。
  • 接受放化疗的晚期颈部淋巴结病变患者,治疗完成后 12 周颈部无 FDG 摄取者无需颈清扫。
  • 无症状患者常规临床随访中复发检出率不足 1%。
  • 唾液腺癌及黏液表皮样、腺样囊性、透明细胞组织学肿瘤 FDG 亲和性低,尤其复发时;FDG PET-CT 无法可靠检测神经周围侵犯。

关键数值与推荐

  • 接受放化疗的晚期颈部淋巴结病变患者,治疗完成后 12 周颈部无 FDG 摄取者无需颈清扫。
  • 无症状患者常规临床随访中复发检出率不足 1%。
  • 非鳞状细胞头颈癌患者如考虑使用 FDG PET-CT,应做基线 FDG PET-CT 以确保肿瘤有亲和性。

临床怎么用

  • FDG PET-CT 可用于 T4 期下咽癌、鼻咽癌及 N3 淋巴结病变分期。
  • 放化疗后 12 周颈部无 FDG 摄取的晚期淋巴结病变患者可避免颈清扫。
  • FDG PET-CT 可能有助于对幸存者进行风险分层,制定最佳监测路径。
  • 非鳞状细胞头颈癌使用 FDG PET-CT 前应做基线检查确认肿瘤亲和性。

局限性

  • 唾液腺癌及黏液表皮样、腺样囊性、透明细胞组织学肿瘤 FDG 亲和性低,尤其复发时。
  • FDG PET-CT 无法可靠检测神经周围侵犯。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

FDG PET-CT is one the main investigations for squamous cell (Sq) head and neck (H&N) cancer patients. FDG PET-CT has a key role for the staging of patients with T4 cancer of the hypopharynx and nasopharynx and patients with N3 nodal disease. It is effective in detecting recurrent disease accurately. In addition, it has an emerging role in the surveillance of Sq H&N cancer survivors. In patients with advanced neck nodal disease treated with chemoradiotherapy, there is compelling evidence that patients with no FDG uptake in the neck 12 weeks following completion of treatment do not require neck dissection. There is considerable interest in using FDG PET-CT for develop more effective clinical pathways for the surveillance of Sq H&N cancer. Currently, the detection rate of recurrence in patients who attend regular clinical follow-up is poor, less than 1% in asymptomatic patients. FDG PET-CT may enable survivors to be stratified into groups based on the likelihood of having recurrent disease. Optimal surveillance pathways can be developed, reserving most intense imaging regimes and most frequent follow-up for survivors at high risk of recurrence. FDG PET CT is sometimes considered for patients with non Sq H&N cancer. If used in this context, a baseline FDG PET-CT should be done to ensure that the tumour is avid. Most H&N malignant tumours are avid. However, salivary gland cancers, and tumours with muco-epidermoid, adenoid cystic and clear cell histology show paucity of FDG avidity, especially when they recur. In addition, peri-neural invasion cannot be detected reliably with FDG PET-CT.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wong WL. PET-CT for Staging and Detection of Recurrence of Head and Neck Cancer. Semin Nucl Med. 2020. PMID: 33246535. doi:10.1053/j.semnuclmed.2020.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。